| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 4959- | PEITC, | Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment |
| - | in-vitro, | Ovarian, | NA |
| 4935- | PEITC, | Phenethyl Isothiocyanate Suppresses Inhibitor of Apoptosis Family Protein Expression in Prostate Cancer Cells in Culture and In Vivo |
| - | in-vivo, | Pca, | LNCaP | - | in-vivo, | Pca, | PC3 |
| 4944- | PEITC, | Phenethyl isothiocyanate induces DNA damage-associated G2/M arrest and subsequent apoptosis in oral cancer cells with varying p53 mutations |
| - | in-vitro, | Oral, | NA |
| 4926- | PEITC, | PEITC inhibits the invasion and migration of colorectal cancer cells by blocking TGF-β-induced EMT |
| - | in-vitro, | CRC, | SW48 |
| 4929- | PEITC, | PacT, | Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 4934- | PEITC, | Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 4943- | PEITC, | Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: role of caspase and MAPK activation |
| - | in-vitro, | Ovarian, | OVCAR-3 |
| 5183- | PEITC, | Cisplatin, | Phenethyl Isothiocyanate Induces Apoptosis Through ROS Generation and Caspase-3 Activation in Cervical Cancer Cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HaCaT |
| 5184- | PEITC, | Phenethyl isothiocyanate exhibits antileukemic activity in vitro and in vivo by inactivation of Akt and activation of JNK pathways |
| - | vitro+vivo, | AML, | U937 |
| 5186- | PEITC, | Phenethyl Isothiocyanate inhibits STAT3 activation in prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 1767- | PG, | Propyl gallate induces cell death in human pulmonary fibroblast through increasing reactive oxygen species levels and depleting glutathione |
| - | in-vitro, | Nor, | NA |
| 1769- | PG, | The Anti-Apoptotic Effects of Caspase Inhibitors in Propyl Gallate-Treated Lung Cancer Cells Are Related to Changes in Reactive Oxygen Species and Glutathione Levels |
| - | in-vitro, | Lung, | Calu-6 | - | in-vitro, | Lung, | A549 |
| 1770- | PG, | Propyl gallate sensitizes human lung cancer cells to cisplatin-induced apoptosis by targeting heme oxygenase-1 for TRC8-mediated degradation |
| - | in-vitro, | Lung, | NA |
| 1765- | PG, | Enhanced cell death effects of MAP kinase inhibitors in propyl gallate-treated lung cancer cells are related to increased ROS levels and GSH depletion |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | Calu-6 |
| 1254- | PI, | VitC, | Piperlongumine combined with vitamin C as a new adjuvant therapy against gastric cancer regulates the ROS–STAT3 pathway |
| - | in-vivo, | GC, | NA |
| 3587- | PI, | Piperine: A review of its biological effects |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3595- | PI, | Black pepper and health claims: a comprehensive treatise |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 5215- | PI, | Piperine impairs cell cycle progression and causes reactive oxygen species-dependent apoptosis in rectal cancer cells |
| - | in-vitro, | CRC, | NA |
| 2966- | PL, | A strategy to improve the solubility and bioavailability of the insoluble drug piperlongumine through albumin nanoparticles |
| - | in-vitro, | LiverDam, | NA |
| 2968- | PL, | Chit, | efficient_cancer_therapy">Preparation of piperlongumine-loaded chitosan nanoparticles for safe and efficient cancer therapy |
| - | in-vitro, | GC, | AGS |
| 2956- | PL, | Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis |
| - | in-vitro, | PC, | NA |
| 2964- | PL, | Preformulation Studies on Piperlongumine |
| - | Analysis, | Nor, | NA |
| 2940- | PL, | Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Kidney, | 786-O | - | in-vitro, | BC, | SkBr3 |
| 2943- | PL, | Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Lung, | A549 | - | in-vitro, | BC, | MCF7 |
| 2944- | PL, | Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells |
| - | in-vitro, | Thyroid, | IHH4 | - | in-vitro, | Thyroid, | 8505C | - | in-vivo, | NA, | NA |
| 2946- | PL, | Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent |
| - | Review, | Var, | NA |
| 2949- | PL, | Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
| 2951- | PL, | AF, | Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells |
| - | in-vitro, | GBM, | U87MG |
| 2953- | PL, | Piperlongumine Acts as an Immunosuppressant by Exerting Prooxidative Effects in Human T Cells Resulting in Diminished TH17 but Enhanced Treg Differentiation |
| - | in-vitro, | Nor, | NA |
| 2965- | PL, | docx, | Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple negative breast cancer |
| - | Analysis, | Var, | NA |
| 2962- | PL, | Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2‑Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents |
| - | in-vitro, | Nor, | PC12 |
| 2958- | PL, | Natural product piperlongumine inhibits proliferation of oral squamous carcinoma cells by inducing ferroptosis and inhibiting intracellular antioxidant capacity |
| - | in-vitro, | Oral, | HSC3 |
| 2957- | PL, | Piperlongumine Induces Cell Cycle Arrest via Reactive Oxygen Species Accumulation and IKKβ Suppression in Human Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 |
| 1940- | PL, | Piperlongumine Inhibits Migration of Glioblastoma Cells via Activation of ROS-Dependent p38 and JNK Signaling Pathways |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
| 1946- | PL, | PI, | Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling |
| - | in-vitro, | Liver, | NA |
| 1947- | PL, | Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | NA |
| 1948- | PL, | BNL, | Natural borneol serves as an adjuvant agent to promote the cellular uptake of piperlongumine for improving its antiglioma efficacy |
| - | in-vitro, | GBM, | NA |
| 1950- | PL, | Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Lung, | A549 |
| 1951- | PL, | Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation |
| - | in-vitro, | Lung, | A549 |
| 1952- | PL, | 5-FU, | Piperlongumine induces ROS accumulation to reverse resistance of 5-FU in human colorectal cancer via targeting TrxR |
| - | in-vivo, | CRC, | HCT8 |
| 1944- | PL, | Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress |
| - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 |
| 1941- | PL, | Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer |
| - | in-vitro, | HNSCC, | NA |
| 1939- | PL, | Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | HUH7 | - | in-vivo, | NA, | NA |
| 2004- | PLB, | Plumbagin Inhibits Proliferative and Inflammatory Responses of T Cells Independent of ROS Generation But by Modulating Intracellular Thiols |
| - | in-vivo, | Var, | NA |
| 2006- | PLB, | Plumbagin induces apoptosis in human osteosarcoma through ROS generation, endoplasmic reticulum stress and mitochondrial apoptosis pathway |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | Nor, | hFOB1.19 |
| 2005- | PLB, | Plumbagin induces apoptosis in lymphoma cells via oxidative stress mediated glutathionylation and inhibition of mitogen-activated protein kinase phosphatases (MKP1/2) |
| - | in-vivo, | Nor, | EL4 | - | in-vitro, | AML, | Jurkat |
| 5163- | PLB, | Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells |
| - | in-vitro, | SCC, | SCC25 |
| 5162- | PLB, | Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells |
| - | vitro+vivo, | Melanoma, | A172 |
| 5161- | PLB, | Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells |
| - | in-vitro, | SCC, | SCC25 |
| 5159- | PLB, | Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression |
| - | in-vitro, | AML, | K562 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid